Brief: Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin And Glp-1 Programs For Chronic Weight Management
BRIEF-Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin And Glp-1 Programs For Chronic Weight Management Sept 8 (Reuters) - Structure Therapeutics Inc. GPCR.O:
STRUCTURE THERAPEUTICS REPORTS POSITIVE CLINICAL DATA ACROSS ORAL SMALL MOLECULE AMYLIN AND GLP-1 PROGRAMS FOR CHRONIC WEIGHT MANAGEMENT
STRUCTURE THERAPEUTICS - ADDITIONAL CLINICAL DATA FOR ALENIGLIPRON EXPECTED IN Q4 2026
STRUCTURE THERAPEUTICS - ACCG-2671 DEMONSTRATES ABOUT 6-DAY HALF-LIFE, NO SERIOUS ADVERSE EVENTS, 3.3% BODY WEIGHT LOSS IN PHASE 1/2A SAD TRIAL
STRUCTURE THERAPEUTICS - FIRST PARTICIPANTS DOSED WITH ACCG-2671 IN 12-WEEK MAD PHASE 1/2A TRIAL; TOPLINE DATA EXPECTED 1H 2027
STRUCTURE THERAPEUTICS - ALENIGLIPRON DEMONSTRATES UP TO 16.2% BODY WEIGHT REDUCTION AT 72 WEEKS IN ACCESS OLE TRIAL
Source text: ID:nGNX64S8Fk
Further company coverage: GPCR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Structure Therapeutics
See all newsFactbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Structure falls as investors await more obesity trial data, says Jefferies